Peri-operative chemotherapy for resectable colorectal liver metastasis: Does timing of systemic therapy matter?

Journal of Surgical Oncology

Volumn 105, Issue 6, 2012, Pages 511-519

  Pinto Marques, Hugo ^a   Barroso, Eduardo ^a   De Jong, Mechteld C ^b   Choti, Michael A ^b   Ribeiro, Vasco ^a   Nobre, Ana Marta ^a   Carvalho, Carlos ^a   Pawlik, Timothy M ^b  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

chemotherapy; colorectal; liver; metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; DATA BASE; DISEASE FREE SURVIVAL; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; POSTOPERATIVE COMPLICATIONS; PROPENSITY SCORE; YOUNG ADULT;

EID: 84859715398     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22133     Document Type: Article

References (35)

1. de Jong MC, Pulitano C, Ribero D, et al.: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250: 440-448.
2. Folprecht G, Gruenberger T, Bechstein WO, et al.: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11: 38-47.
3. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
4. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-658.
5. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016.
6. Pawlik TM, Cosgrove D,: The role of peri-operative chemotherapy for resectable colorectal liver metastasis: What does the evidence support? J Gastrointest Surg 15: 410-415.
7. Chua TC, Saxena A, Liauw W, et al.: Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17: 492-501.
8. Reddy SK, Zorzi D, Lum YW, et al.: Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann Surg Oncol 2009; 16: 1809-1819.
9. Adam R, Laurent A, Azoulay D, et al.: Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777-785.
10. Tsai S, Marques HP, de Jong MC, et al.: Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 12: 262-269.
11. Therasse P, Eisenhauer EA, Verweij J,: RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031-1039.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
13. Clavien PA, Strasberg SM,: Severity grading of surgical complications. Ann Surg 2009; 250: 197-198.
14. Clavien PA, Barkun J, de Oliveira ML, et al.: The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009; 250: 187-196.
15. Dindo D, Demartines N, Clavien PA,: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
16. Kaplan ELMP,: Nonparametric from estimation incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Gleisner AL, Choti MA, Assumpcao L, et al.: Colorectal liver metastases: Recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008; 143: 1204-1212.
18. Newgard CD, Hedges JR, Arthur M, et al. Advanced statistics: The propensity score-a method for estimating treatment effect in observational research. Acad Emerg Med 2004; 11: 953-961.
19. Rubin DB,: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
20. de Jong MC, Mayo SC, Pulitano C, et al.: Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: Results from an international multi-institutional analysis. J Gastrointest Surg 2009; 13: 2141-2151.
21. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al.: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580.
22. Nuzzo G, Giuliante F, Ardito F, et al.: Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007; 11: 318-324.
23. Power DG, Kemeny NE,: Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol; 28: 2300-2309.
24. Lubezky N, Geva R, Shmueli E, et al.: Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases? World J Surg 2009; 33: 1028-1034.
25. Reddy SK, Broadwater G, Niedzwiecki D, et al.: Multiagent chemotherapy for isolated colorectal liver metastases: A single-centered retrospective study. J Gastrointest Surg 2009; 13: 74-84.
26. Pawlik TM, Olino K, Gleisner AL, et al.: Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868.
27. Pawlik TM, Choti MA,: Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11: 1057-1077.
28. Scoggins CR, Campbell ML, Landry CS, et al.: Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009; 16: 35-41.
29. Gruenberger B, Tamandl D, Schueller J, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
30. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
31. Kooby DA, Fong Y, Suriawinata A, et al.: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-1044.
32. Sahajpal A, Vollmer CM Jr, Dixon E, et al.: Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol 2007; 95: 22-27.
33. Vauthey JN, Nordlinger B, Kopetz S, et al. Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: A debate over goals of research and an approach while the jury remains out. Ann Surg Oncol 17: 1983-1986.
34. Nordlinger B, Vauthey JN, Poston G, et al.: The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9: 212-218.
35. Hewes JC, Dighe S, Morris RW, et al.: Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg 2007; 31: 353-364; discussion 65-6.